Related by context. All words. (Click for frequent words.) 78 Meets Primary Endpoint 76 Phase IIb Trial 76 Dasatinib 76 Anti Tumor 76 dasatinib Sprycel ® 76 Patients Treated With 76 PEGylated Fab fragment 76 Prolongs Survival 76 Novel Oral 76 Drug Candidate 75 Complicated Skin 75 Phase 2b Clinical Trial 75 GW# [003] 75 Initiate Clinical Trial 75 Improves Outcomes 75 Mg Usa 75 beta 1a 75 Is Well Tolerated 75 Antitumor Activity 75 Adjuvant Treatment 75 Kinase Inhibitor 75 Hormone Refractory Prostate Cancer 75 Irinotecan 75 Pegylated 75 Ziprasidone 75 Tyrosine Kinase Inhibitor 75 Files IND 74 Temsirolimus 74 Demonstrates Significant 74 Romiplostim 74 Oral Fingolimod 74 FDA APPROVES 74 Receptor Agonist 74 SPRYCEL ® 74 Recombinant Human 74 Severe Sepsis 74 Melphalan 74 Pharmacokinetics PK 74 Demonstrates Positive 74 Investigational Compound 74 Shows Efficacy 74 Nilotinib 74 Hsp# Inhibitor 74 Receives Orphan Drug Designation 74 Relapsed Refractory 74 dual endothelin receptor antagonist 74 dasatinib Sprycel 74 AVASTIN 74 Plaque Psoriasis 74 receptor tyrosine kinase inhibitor 74 Study Evaluating 74 Single Dose 74 Investigational Agent 74 Treated Patients 74 Personalized Immunotherapy 74 FDA Okays 74 Demonstrates Efficacy 74 Degarelix 73 Pertuzumab 73 Aurora Kinase 73 Demonstrated Significant 73 Fluticasone 73 NDA Submission 73 Prospective Randomized 73 Initiate Phase 73 Bucindolol 73 Investigational Treatment 73 Pafuramidine 73 Epidermal Growth Factor Receptor 73 vapreotide acetate 73 PEGylated anti 73 Mg Uk 73 Vidaza azacitidine 73 Liposomal 73 TNF Tumor Necrosis Factor 73 Rheumatoid Arthritis Drug 73 Zorbtive TM 73 leukotriene receptor antagonist 73 Submits NDA 73 Clinical Trial Evaluating 73 Aflibercept 73 Successfully Completes Phase 73 Phase 2b Trial 73 Phase 2a Trial 73 Antiviral Activity 73 HDAC Inhibitor 73 Granted Orphan Drug 73 Phase III Clinical Trial 73 alfa 2a 73 Posaconazole 73 Tezampanel 73 Epratuzumab 73 Combination REOLYSIN R 73 Intravitreal 73 R Saizen R 73 Long Term Efficacy 73 Improves Survival 73 Teva Provides Update 73 Peginterferon alfa 2b 73 Advanced Melanoma 73 Anti Tumor Activity 73 Completes Patient Enrollment 73 Pemetrexed 73 Polymerase Inhibitor 72 Mycophenolate Mofetil 72 Phase III Trial 72 pan histone deacetylase 72 Parathyroid Hormone 72 Sipuleucel T 72 Glufosfamide 72 Shows Statistically Significant 72 Granulocyte Colony Stimulating Factor 72 Cyclooxygenase 2 72 Lenalidomide 72 TO AVOID PREGNANCY WHILE 72 Combination Therapy 72 AAG geldanamycin analog 72 Combination Treatment 72 Oral Formulation 72 Vidofludimus 72 topical gel formulation 72 Safinamide 72 Fulvestrant 72 Aliskiren 72 Pooled Analysis 72 Talabostat 72 See CLINICAL PHARMACOLOGY 72 Fondaparinux 72 Phase 2b Study 72 ZOLINZA 72 mTOR mammalian target 72 Previously Treated 72 Maribavir 72 Abatacept 72 Orally Active 72 Fludarabine 72 Newly Diagnosed Multiple Myeloma 72 Pivotal Phase III 72 Dapagliflozin 72 CYP#A# substrate 72 Peginterferon Alfa 2a 72 Clinical Trial Results 72 Renal Cell Carcinoma 72 myelodysplastic myeloproliferative diseases 72 ® lenalidomide 72 Trial Evaluating 72 Achieves Primary Endpoint 72 vinorelbine tartrate 72 Systemic Delivery 72 Ranolazine 72 Anthracycline 72 Cutaneous T 72 non nucleoside inhibitor 72 FDA Accepts 72 Medoxomil 72 Sapacitabine 72 Denufosol 72 CYP#A# CYP#D# 72 Peginterferon 72 oral prodrug 72 Shows Promise Against 72 Patients Receiving 72 imatinib Gleevec ® 72 hypereosinophilic syndrome 72 JAK Inhibitor 72 sorafenib Nexavar 72 Advanced Renal Cell 72 Significantly Improved 72 HER2 Positive Breast Cancer 72 Moxifloxacin 72 IND Application 72 Novel Compound 72 Monotherapy 72 Prostate Cancer Vaccine 72 Angiotensin Converting Enzyme 71 Initiates Clinical 71 Omacetaxine 71 FDA Approvals 71 Neoadjuvant 71 Low Dose 71 Fingolimod 71 Pivotal Study 71 Silodosin 71 Patients Treated 71 chronic eosinophilic leukemia 71 Demonstrates Potent 71 Phase 2a Clinical Trial 71 Disease Progression 71 Phase IIb Clinical Trial 71 Eculizumab 71 Archexin 71 Trabectedin 71 liposomal formulation 71 LymphoStat B belimumab 71 Protease Inhibitor 71 Desvenlafaxine 71 Bosentan 71 R lenalidomide 71 docetaxel Taxotere ® 71 Ropinirole 71 Tigecycline 71 Initiates Enrollment 71 nilotinib Tasigna 71 Mylan Receives Approval 71 alefacept 71 Initiates Clinical Trial 71 Chronic Hepatitis C 71 Pulmonary Arterial Hypertension 71 Lung Cancer Drug 71 Receptor Antagonist 71 PKC# 71 histone deacetylase HDAC inhibitor 71 erlotinib Tarceva ® 71 Tipranavir 71 Soft Tissue Sarcoma 71 highly selective inhibitor 71 HCV Protease Inhibitor 71 paclitaxel Taxol 71 Bendamustine 71 Bivalirudin 71 Pivotal Phase 71 Zileuton 71 thalidomide Thalomid 71 Gefitinib 71 Bayer Onyx 71 Dalbavancin 71 Refractory Hodgkin Lymphoma 71 Psoriasis Drug 71 Montelukast 71 Phase IIa Clinical Trial 71 ritonavir boosted 71 sodium glucose cotransporter 71 Secondary Hyperparathyroidism 71 Signaling Pathway 71 IMiDs ® 71 Nitazoxanide 71 Inhaled Corticosteroids 71 Ambrisentan 71 pregabalin Lyrica 71 lamotrigine Lamictal 71 FUSILEV enhances 71 metastatic malignant 71 Oral Spray 71 Deforolimus 71 Rotavirus Vaccine 71 Factor Receptor 71 Vaccine Adjuvant 71 Immunotherapeutic 71 Interferon beta 1a 71 Noxafil 71 Vildagliptin 71 Lupus Nephritis 71 Enzastaurin 71 Paliperidone Palmitate 71 Lupus Drug 71 Presents Preclinical Data 71 CYT# potent vascular disrupting 71 sunitinib Sutent ® 71 Myelofibrosis 71 Interferon Beta 71 Pramlintide 71 Nucleoside 71 itraconazole Sporanox 71 selective modulator 71 Files Investigational 71 Febuxostat 71 Toremifene 71 antibody MAb 71 Transdermal Patch 71 Nebulized 71 Acute Ischemic Stroke 71 icatibant 71 targeted antifolate 71 Fludara ® 71 cetuximab Erbitux ® 71 Demonstrates Potential 71 selective A2A adenosine receptor 71 Zarnestra 71 Appears Safe 70 Chronic Myeloid Leukemia 70 LAB CGRP 70 Ustekinumab 70 Bazedoxifene 70 Novel Inhibitor 70 Tesamorelin 70 Inhalation Aerosol 70 Darunavir 70 serotonin norepinephrine reuptake inhibitor 70 Preclinical Data 70 Adalimumab 70 Interferon Alpha 70 Tiotropium 70 Diabetic Neuropathy 70 Vaginal Gel 70 topically administered 70 Pharmacokinetic Study 70 Gleevec resistant 70 Paraplatin ® 70 Protease Inhibitors 70 Efficacy Trial 70 novel VDA molecule 70 Investigational Drug 70 Pazopanib 70 Tocilizumab 70 Dose Ranging Study 70 gefitinib Iressa 70 adalimumab Humira 70 Phase Ib Clinical Trial 70 Drug Shows Promise 70 Bevacizumab 70 Helicobacter pylori eradication 70 Levoleucovorin 70 Glucocorticoid 70 Pralatrexate 70 Recurrent Glioblastoma 70 Naive Patients 70 Significantly Improves 70 Initiates Phase III 70 Ozarelix 70 Myelodysplastic Syndrome MDS 70 Danazol 70 Xeloda ® 70 Elagolix 70 denileukin diftitox 70 Well Tolerated 70 Allergic Rhinitis 70 Adjuvant Therapy 70 Antitumor 70 cinacalcet 70 nucleoside analog 70 Initiates Clinical Trials 70 First Patient Dosed 70 Antiangiogenic 70 Anticancer Agent 70 Infliximab 70 ribavirin RBV 70 Eszopiclone 70 Lubiprostone 70 Completes Enrollment 70 Gout Drug 70 5 Fluorouracil 70 cetuximab Erbitux R 70 Replacement Therapy 70 Annamycin 70 Carbamazepine 70 Infected Patients 70 Treatment Naïve 70 acyclovir Lauriad R 70 generation purine nucleoside 70 Randomized Double blind 70 Initiates Phase II 70 Patient Enrollment 70 Hepatitis C Genotype 70 Double Blind Placebo 70 Myelodysplastic Syndromes 70 MAGE A3 ASCI 70 Iloperidone 70 Monoclonal Antibody 70 Orally administered 70 ALVESCO ® 70 Hepatocellular 70 Fast Track Status 70 nilotinib Tasigna ® 70 2A receptor agonist 70 Imatinib mesylate 70 administered concomitantly 70 humanized therapeutic 70 Improved Survival 70 Cimetidine 70 Investigational Oral 70 Schizophrenia Treatment 70 Pegloticase 70 peripherally acting 70 Boceprevir 70 Treatment Naive Patients 70 Cardiotoxicity 70 IN PATIENTS WITH 70 Shows Promising 70 Vandetanib 70 Ofatumumab 70 ACE Inhibitors 70 Cilostazol 70 Nicotine Vaccine 70 Vidaza R 70 Improve Survival 70 methylnaltrexone bromide 70 acadesine 70 Blinatumomab 70 Dose Escalation 70 Sevelamer 70 Randomized Phase 70 brand ciclesonide HFA 70 oral dual endothelin 70 Osteoporosis Treatment 70 investigational humanized monoclonal antibody 70 cromolyn sodium 70 SinuNase TM 70 Combo Therapy 70 Cytarabine 70 Oral Cladribine 70 sorafenib tablets 70 Vicriviroc 70 Tumor Necrosis Factor 70 Saquinavir 70 sapropterin dihydrochloride 70 Overactive Bladder 70 Present Preclinical Data 70 Diabetic Nephropathy 70 Remicade infliximab 70 Effectively Treats 70 Myeloid 70 humanized monoclonal 70 Cholesterol Lowering Drug 70 protein tyrosine phosphatase 1B 70 Liprotamase 70 Azacitidine 70 Valopicitabine 70 Plus Ribavirin 70 Cinacalcet 69 Hepatocellular Carcinoma 69 Osteoporosis Drug 69 fosbretabulin 69 treat chronic sinusitis 69 Atypical Hemolytic Uremic Syndrome 69 refractory chronic lymphocytic 69 Prophylactic Treatment 69 Ganciclovir 69 Camptosar ® 69 Immunomodulatory 69 Benign Prostatic Hyperplasia 69 ara C 69 Simulect 69 Vinorelbine 69 Receives Positive Opinion 69 demonstrated antitumor activity 69 INSPIRE Trial Phase III 69 Inhibits 69 Nexavar ® 69 YONDELIS R 69 ADP receptor antagonist 69 Treatment Regimen 69 reslizumab 69 Isavuconazole 69 Cyclophosphamide 69 YONDELIS 69 JAK2 Inhibitor 69 Enzyme Replacement Therapy 69 Chronic Heart Failure 69 Bicalutamide 69 Antigen Specific 69 Initiated Phase 69 Adjuvant Chemotherapy 69 Diffuse Large B 69 Lamotrigine 69 Ecallantide 69 Chronic Lymphocytic Leukemia 69 Progressive Multifocal Leukoencephalopathy 69 Phase III Trials 69 Myeloma Patients 69 ANDA Filing 69 chimeric monoclonal antibody 69 Daptomycin 69 Transdermal Delivery 69 Ischemic Stroke 69 Hypertensive Patients 69 Pivotal Trial 69 Doripenem 69 PEG IFN 69 Bronchodilator 69 MetroGel 69 alpha 2a 69 ARIXTRA R 69 Survival Benefit 69 Oral Calcitonin 69 Conjugate 69 Antiarrhythmic 69 Transdermal System 69 Epilepsy Drug 69 5 HT4 69 Hydrochlorothiazide Tablets 69 Idiopathic Pulmonary Fibrosis 69 Advanced Prostate Cancer 69 Betaferon R 69 Therapeutic Vaccine 69 Metabolic Disorder 69 Prodrug 69 TLK# 69 Drug Resistant 69 Hedgehog Pathway Inhibitor 69 Novel Antibiotic 69 Receives Approvable Letter 69 Antipsychotic 69 Parnate 69 Receptor Antagonists 69 Maleate 69 Relapsing Remitting Multiple Sclerosis 69 developing Bicifadine serotonin 69 Treating Chronic 69 Adjunctive Therapy 69 IMiDs ® compound 69 Generic Versions 69 Controlled Study 69 Previously Untreated 69 Potent Inhibitor 69 Treatment Reduces 69 evaluating tivozanib 69 Study Showed 69 REMINYL ® 69 orally inhaled migraine 69 Follicular Lymphoma 69 Fluorouracil 69 Elderly Patients 69 Rilonacept 69 Expanded Indication 69 Xyfid TM 69 Fungal Infections 69 boosted protease inhibitor 69 Vertex hepatitis C 69 targeting CD# 69 Kepivance 69 MKC# MKC# PP 69 Autologous Stem Cell Transplantation 69 5 HT3 antagonist 69 Methylnaltrexone 69 Schizophrenia Drug 69 Generic Version 69 Atomoxetine 69 Teriparatide 69 Budesonide 69 Ramelteon 69 Breast Cancer Recurrence 69 Thiazolidinediones 69 PDE4 inhibitor 69 Interferon Gamma 69 Diuretic 69 Rheumatoid Arthritis Patients 69 Inhalation Solution 69 Announces Tentative Approval 69 Leukemias 69 nucleotide analogue 69 Dyloject TM 69 Zoloft sertraline 69 Cytotoxic 69 Pegylated Liposomal Doxorubicin 69 BAL# [002] 69 pan HDAC inhibitor 69 XYOTAX TM 69 Relapsing Multiple Sclerosis 69 Ixabepilone 69 PRN FDA Approves 69 Interferon beta 1b 69 Vitro Activity 69 Onconase 69 Study Demonstrates 69 Ceflatonin R 69 Interferon alfa 69 Daclizumab 69 Ridaforolimus 69 oropharyngeal candidiasis OPC 69 Unstable Angina 69 CIMZIA R 69 Piperacillin 69 bortezomib Velcade 69 meropenem 69 Levaquin levofloxacin 69 ORENCIA ® 69 Proven Effective 69 Squalamine 69 HCV RNA polymerase 69 Golimumab 69 Therapeutic Efficacy 69 Certolizumab pegol 69 Tyrosine Kinase Inhibitors 69 Arthritis Drug 69 II Clinical Trial 69 Disease Modifying 69 Showed Significant 69 Postmenopausal Osteoporosis 69 Hypercholesterolemia 69 BCG refractory carcinoma 69 SUTENT ® 69 Node Positive 69 Coadministration 69 Multiple Ascending Dose 69 small molecule tyrosine 69 polymerase inhibitor 69 Erlotinib 69 sunitinib Sutent 69 NS5B polymerase 69 STELARA TM 69 ALVESCO R 69 Receives Marketing Authorization 69 Tolvaptan 69 HMG CoA reductase inhibitors 69 Luteinizing Hormone Releasing Hormone 69 pediatric Crohn disease 69 Mitoxantrone 69 Zeldox 69 Therapy Reduces 69 Bortezomib 69 alkylating agent 69 Hospital Acquired Pneumonia 69 ACTEMRA TM 69 Primary Hypercholesterolemia 69 Demonstrates Statistically Significant 69 polycythemia vera essential thrombocythemia 69 Pirfenidone 69 SPIRIVA ® 69 Omalizumab 69 ergot derivatives 69 Tasimelteon 69 Formoterol 68 Roche Actemra 68 vinca alkaloid 68 NAVISTAR R 68 Controlled Trial 68 Castration Resistant Prostate Cancer 68 Interferon beta 68 gastrointestinal stromal tumors GIST 68 Initiate Phase III 68 RoACTEMRA 68 Non Alcoholic Steatohepatitis 68 Preclinical Study 68 Antiviral Therapy 68 HER2 Positive 68 Migraine Treatment 68 Muraglitazar 68 lansoprazole Prevacid 68 Hemodialysis Patients 68 investigational pharmacologically unique 68 FEMALES SHOULD BE ADVISED 68 Etanercept 68 Estrogen Receptor 68 Subgroup Analysis 68 Tasigna nilotinib 68 non peptidic protease 68 Vascular Disrupting Agent 68 Unfractionated Heparin 68 Chronic Sinusitis 68 AVAPRO 68 Chronic Hepatitis B 68 Fixed Dose 68 panitumumab Vectibix 68 platelet inhibitor 68 CYT# QbG# 68 First Patient Enrolled 68 Blood Pressure Drug 68 FDA Clears 68 Pharmacodynamics 68 lexidronam injection 68 TNF Blockers 68 Demonstrates Sustained 68 Cethromycin 68 Double Blind Randomized 68 Cancidas 68 Initiates Phase 2b 68 Anticancer Drug 68 orally administered inhibitor 68 PHASE III 68 R bisoprolol Euthyrox 68 Gastrointestinal Stromal Tumors 68 selective antagonist 68 Glatiramer Acetate 68 ABLYNX 68 Ocrelizumab 68 PNP inhibitor 68 Decitabine 68 Platinol ® 68 Fluconazole 68 Confirms Efficacy 68 mertansine 68 Methylprednisolone 68 selective phosphodiesterase 68 HuMax TAC 68 Begins Dosing 68 mTOR inhibitor 68 Resistant Hypertension 68 Kinoid 68 Presents Positive 68 IL# PE#QQR 68 oral dihydropyrimidine dehydrogenase DPD 68 Phase 1b Clinical Trial 68 Pathway Inhibitor 68 Metastatic Melanoma 68 Commences Phase 68 Cypher Sirolimus 68 bevacizumab Avastin ® 68 Heterozygous Familial Hypercholesterolemia 68 novel histone deacetylase 68 ciprofloxacin hydrochloride 68 Pegylated Interferon 68 Capsules CII 68 Inflammatory Arthritis 68 xanthine oxidase inhibitor 68 Fracture Risk 68 Demonstrate Significant 68 D aspartate NMDA receptor 68 Dementia Related Psychosis 68 Ciclesonide 68 aripiprazole Abilify 68 Known hypersensitivity 68 Topotecan 68 Kit CD# positive 68 somatostatin analog 68 Metastatic Prostate Cancer 68 Anticoagulant 68 Ovitrelle R Serostim 68 Vimpat R 68 Extended Release 68 Renal Impairment 68 Crofelemer budesonide foam 68 raloxifene Evista 68 Atopic Dermatitis 68 Prostatic 68 Elotuzumab 68 etanercept Enbrel 68 Anemia Drug 68 Actonel risedronate 68 Anti VEGF 68 LymphoStat B TM 68 5 FU leucovorin 68 FASLODEX 68 Avanafil 68 Antihypertensive 68 reuptake inhibitor 68 Attenuates 68 Metastatic Colorectal Cancer 68 Philadelphia Chromosome Positive 68 MKC# MT 68 Randomized Study 68 relapsed MM 68 Novel Therapeutic 68 Interferon gamma 68 targeted radiotherapeutic 68 #mg/#mg 68 Advanced Colorectal Cancer 68 Bone Metastases 68 Drug Fails 68 Warfarin Coumadin 68 Bremelanotide 68 Olaparib 68 estramustine 68 cisplatin gemcitabine 68 abacavir sulfate lamivudine 68 CIMZIA TM 68 accumulate preferentially 68 Indomethacin 68 essential thrombocythemia ET 68 Etravirine 68 inhalation aerosol 68 Interferon Alfa 68 Imatinib 68 Enlarged Prostate 68 Mutational 68 Aztreonam Lysine 68 sitagliptin metformin 68 Interferon alfa 2b 68 urate oxidase 68 proteasome inhibitor 68 Proteasome 68 BCR ABL inhibitor 68 sublingual formulation 68 albiglutide 68 Severe Asthma 68 Pregabalin 68 Pediatric Patients 68 Respiratory Virus 68 Begin Clinical Trials 68 topically applied SEPA 68 Preclinical Models 68 cell lymphoma CTCL 68 Clinical Efficacy 68 Hepatic Encephalopathy 68 Immunosuppressant 68 mu opioid receptor antagonist 68 NICE Recommends 68 Trastuzumab 68 IAP inhibitor 68 acetonide FA 68 Crit Rev 68 imatinib Gleevec 68 IIa Clinical Trial 68 Sustained Release 68 Statistically Significant 68 First Patient Treated 68 Laquinimod 68 rasagiline tablets 68 Panzem R 68 Epoetin Alfa 68 Anticancer Activity 68 Anti TNF 68 Candesartan 68 erlotinib Tarceva R 68 Dabigatran etexilate 68 R metformin Concor 68 Diabetic Patients 68 Intravenous Formulation 68 topoisomerase II inhibitor 68 cathepsin K inhibitor 68 Inhaled Nitric Oxide 68 ALN HPN 68 #-# Full Text 68 Tumor Response 68 thetreatment 68 BUPHENYL R sodium phenylbutyrate 68 R memantine HCl 68 cortisol synthesis 68 receptor blocker 68 Analgesic 68 monoclonal antibody IgG1 Mab 68 EVIZON TM 68 tigecycline 68 Integrase Inhibitor 68 RNAi Therapeutic 68 Mimetics 68 Ovidrel 68 dexamethasone Decadron 68 EGFR TKI 68 PEGINTRON TM 68 Desvenlafaxine Succinate 68 Mouse Model 68 familial amyloidotic polyneuropathy FAP 68 COLLABORATION WITH 68 Tumor Growth 68 adenosine injection 68 Epirubicin 68 By JENNIFER LEARN 68 Romidepsin 68 Natalizumab 68 octreotide acetate 68 EnteroMedics proprietary neuroblocking technology 68 lucinactant 68 Pfizer Camptosar 68 Rheumatoid Arthritis RA 68 Bisphosphonate 68 mesylate 68 Locked Nucleic Acid LNA 68 Confirmatory Phase 68 microtubule inhibitor 68 Reduced Risk 68 pioglitazone hydrochloride 68 Antifungal 68 M# rationally 68 CIMZIA TM certolizumab pegol 68 Synta Announces 68 Kidney Transplant Patients 68 Mipomersen 68 phase III isavuconazole 68 novel emulsion formulation 68 Skeletal Muscle 68 Diabetic Foot Ulcer 68 folate analogue metabolic 68 PEG interferon 68 Genentech Rituxan 68 relapsing multiple sclerosis 68 Tesetaxel 68 leukemia AML 68 Catena ® 68 Initiates Phase 68 intranasal formulation 68 Angiogenic 68 benzoic acid hyoscyamine sulfate 68 Launches Generic Version 68 imatinib resistant 68 Pruvel TM 67 Lung Cancer Trial 67 kidney urologic 67 multikinase inhibitor 67 FOR FURTHER INFORMATION ABOUT 67 Targeted Therapy 67 ACE Inhibitor 67 metastatic colorectal 67 Postherpetic Neuralgia 67 Ixempra 67 Taclonex Scalp R 67 multi kinase inhibitor 67 Certolizumab 67 R sorafenib tablets 67 Adefovir 67 receptor modulators 67 Immunomedics Announces 67 Calcium Acetate 67 AnaSpec Introduces 67 sitaxsentan 67 Copegus ® 67 Clostridium difficile Infection 67 Randomized Clinical Trials 67 RhuDex 67 INVANZ 67 including cyclosporine methotrexate 67 plasma kallikrein inhibitor 67 AstraZeneca Symbicort 67 Novel Mechanism 67 Anidulafungin 67 Palonosetron 67 novel synthetic PEGylated 67 Gastric Cancer 67 biliary tract cancer 67 Trandolapril 67 Positive Opinion 67 Malignant Melanoma 67 RELOVAIR ™ 67 Belimumab 67 Cimzia TM 67 interferon beta 1a infertility 67 Placebo Controlled Study 67 Metastatic Renal Cell Carcinoma 67 Clolar ® 67 #/#mg 67 Quinamed 67 Knee Osteoarthritis 67 Antidepressant Drug 67 Copegus ribavirin 67 Chemoradiation 67 Vitrasert R 67 Arranon 67 Randomized Evaluation 67 Lymphocytic 67 Alemtuzumab 67 Cloretazine 67 CDK inhibitor 67 HDACi 67 TNF alpha selectively neutralizing 67 Neulasta R 67 Monoclonal antibody 67 Treatment Experienced 67 selective estrogen receptor modulator 67 Submits Supplemental 67 Radiofrequency Ablation 67 ORADUR ® 67 selective orally bioavailable 67 Levofloxacin 67 immunomodulatory therapy 67 Hepatitis B Vaccine 67 mTOR kinase 67 ULORIC 67 Gonal f ® 67 paroxetine sertraline 67 inhalation powder 67 Ph + acute lymphoblastic 67 unresectable inoperable 67 AKT inhibitor 67 bevacizumab Avastin R 67 2 methoxyestradiol 67 Randomized Phase II 67 baminercept 67 interferon gamma 1b 67 Gleevec imatinib mesylate 67 Phospholipase A2 67 Amgen Neulasta R 67 Rivastigmine 67 diarrhea predominant irritable 67 Fewer Side Effects 67 Intravesical 67 Tacrolimus 67 5alpha reductase 67 Triapine 67 subependymal giant cell 67 Pivotal Trials 67 Aptivus ® 67 TYZEKA 67 novel topoisomerase 67 peptidic compound 67 Known generically 67 Traficet EN 67 orally inhaled 67 IMiDs R 67 Sodium oxybate 67 alpha 2b 67 REPRONEX R menotropins 67 Gemcitabine 67 tazobactam 67 Microplasmin 67 levocetirizine 67 MEK Inhibitor 67 mild vasodilator 67 humanized interleukin 6 67 selective agonist 67 Tapentadol 67 Atypical Antipsychotics 67 ISTODAX ® 67 Systemic Sclerosis 67 Clinical Study Shows 67 5 fluorouracil leucovorin 67 HCl capsules 67 Monopril 67 Aldara ® 67 Rigel R# 67 Tofacitinib 67 Antiplatelet 67 Drug Prevents 67 Anti CD# Antibody 67 WX UK1 67 Janus kinase 67 Oral Insulin 67 rhIGF-I/rhIGFBP-3 67 soluble tumor necrosis 67 product candidate Lpathomab 67 alfa 2b